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Drug Matrix cell C1: Management/supervision: Reducing harm
S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  Methadone cl inic staff can be influenced to adopt a  more pro-maintenance stance (1998). In Austral ia  an officia l  campaign and educational  efforts  shi fted staff
atti tudes  away from achieving abstinence and withdrawal  and towards  long-term treatment a imed at reducing harm. The training a lso helped staff who more
strongly disapproved of drug use to nevertheless  move away from an abstinence-only orientation.
S  Forced discharge and drop-out mean more post-methadone deaths  (1999). Ci tes  US study (1998) which found that in the fi rst year the death rate was  eight times
higher among patients  discharged from a methadone programme than those who had remained in treatment; a l l  nine deaths  were among patients  who had
dropped out or been discharged for breaking programme rules  and two thirds  were overdoses.
K  Slow ‘cascade’ of anti -overdose training from staff to other staff and patients  (2011). Drug service staff in England trained in overdose prevention and recovery
us ing naloxone then trained other staff and opiate-us ing patients , but why on average did each trained cl inician train just one drug user every 11 months? See also
from the same study the effectiveness  report (2008) and a fol low-up report (2009) on some of the trainees  which revealed that tra ining had not overcome their
reluctance to carry around naloxone-fi l led syringes. Other naloxone-based training studies  in cel l  A1.
K  Exchanges  actual ly reduce injecting-related l i tter (2012). A major concern about needle exchanges  is  that after use the injecting equipment they supply wi l l  be
left unsafely dis figuring publ ic areas, but this  US study strongly suggested the opposite.
K  Danger of leaving treatment (2008) Reports  a  large Ita l ian study (2007) which highl ighted the protection against overdose deaths  afforded by being in treatment,
and the danger of leaving with reduced tolerance to opiate drugs  but sti l l  vulnerable to relapse.
K  Supervised consumption cuts  methadone deaths  (2010). From the mid 1990s  Bri tish addiction treatment cl inics  started to require patients  to take their
methadone under medical  supervis ion, preventing divers ion to the i l l i ci t market and thousands of overdose deaths.
K  Methadone treatment reduces  drug-related hospital  care (2011). Norwegian study found that even when some drug use continues, being in methadone treatment
dramatical ly cut drug-related phys ical  complaints  requiring hospital  treatment and (a lso confi rmed by a  s ister study [2013]) that such complaints  rebound i f
patients  are forced to or choose to leave.
R  Don’t restrict supply of injecting equipment (2013). Extens ive UK review updated in 2013 which underpinned NICE guidance (see below) found cons istent
evidence that more l iberal  supply of injecting equipment was  associated with potentia l ly less  risky injecting practices .
R  Chal lenge of reconci l ing community concerns  with needle exchange priori ties  (2003 and 2004). Four-part series  from Findings  highl ights  the chal lenge of freely
distributing the “flood” of injecting equipment needed to curtai l  hepati tis  C and managing local  wariness  about needle exchange fuel led particularly by discarded
syringes.
G  NICE says  abundance is  the objective for injecting equipment provis ion (NICE, 2014). UK’s  officia l  health advisory body says  exchange service managers  should
aim for every injector to have even more steri le injecting equipment than they need for every injection. That means supplying customers  with as  much equipment of
the right kind as  they need rather than l imiting suppl ies  or equipment types, and al lowing them to take equipment for others  – whi le at the same time promoting
moves away from injecting from drug use al together.
G  Scottish guidance on running and commiss ioning needle exchanges  (Scottish Government, 2010). Includes  needs assessment, locations, opening hours , s taff
training, injecting equipment provis ion pol icies , and integration with other services .
G  WHO guide to starting and managing needle and syringe programmes (World Health Organization [etc], 2007). Rare in this  sector to have what is  effectively a
management manual , a  s ign of the importance WHO attaches  to making needle exchanges  as  effective as  poss ible to combat HIV.
G  Scottish Drugs  Forum web naloxone s i te. Offers  resources, advice, guidance, information and news on programmes featuring the drug naloxone which reverses
opiate overdose.
G  Balancing recovery ambition with safety and harm reduction ([UK] National  Treatment Agency for Substance Misuse, 2012). Cl inical  consensus  developed for UK
government on how drug-based treatment for heroin addiction can be made more recovery-oriented without los ing harm reduction benefi ts . See also supplement
(2013) on reviewing patients  to see i f treatment should be changed or ended.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page.
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What is this cell about? As described more fully in the cell A1 bite, about reducing the harms experienced by the user as a result of their
drug use, without necessarily reducing use or seeking to overcome dependence. Common interventions include needle exchanges and
substituting a legally prescribed drug of the same type for the original (and usually illegally obtained) substance, also considered as a
treatment for addiction in row 3. This cell is however not about the content of the intervention (for which see cell A1), but how
implementation and impact are affected by the management functions of selecting, training and managing staff and managing the
intervention programme – much less commonly researched topics.
Where should I start? If you find yourself charged with managing a needle exchange (or starting one up) you will probably bless the
World Health Organization for this guide on how to maximise your programme’s anti-HIV potential, a sign of the importance WHO
attaches to making needle exchanges effective, and in particular, increasing their coverage – officially recognised in the UK and
elsewhere as the key to their success. Just about everything seems included in a text characterised by a matter-of-fact determination to
work out in detail what commitment to the human rights of injectors and to public health means for the nuts and bolts of needle
exchange provision. Another strength is its awareness of what exchanges must key in to – the reality of life for injectors – yet also of the
need for pragmatism and ‘politics’ in responding to community concerns and authorities like the police who can make or break exchange
provision. An example is on page 19, where the guide explains why insisting on one-for-one exchange is bound to lead to some avoidable
sharing of equipment, yet recognises exchanges may need to start this way where there is great distrust and suspicion of needle and
syringe provision.
Highlighted study The risks for heroin users of fatal incidents such as overdose after leaving (or being forced to leave) methadone
treatment and after completing detoxification are fairly well recognised. From Italy, the huge Italian VEdeTTE study, which tracked 10,454
heroin users starting treatment in 1998–2001, showed that the risks of leaving treatment are more general than that. The linked Findings
analysis focuses on overdose deaths after detoxification and residential rehabilitation, but in the VEdeTTE study the overdose death rate
also rose by a factor of ten after patients had left methadone programmes. Note the differences in who was most at risk: drop-outs from
residential rehabilitation and methadone maintenance, but in outpatient detoxification, the people who did not drop out and completed
the programme. Treatment completion through drug-free discharge is considered a marker of successful treatment, but it seems ‘success’
can sometimes carry a much higher risk of death than failure. Such findings imply that concern in the name of ‘recovery’ to increase drug-
Drug Matrix cell C1: Management/supervision: Reducing harm 03/06/14
http://findings.org.uk/count/downloads/download.php?file=Matrix/Drugs/C1.htm 1 / 2
free treatment completions and to meet patients’ ambitions to stop taking opiate-type drugs, must be tempered by awareness of the
risks.
Issues to think about
 Does staying safe(r) mean staying? Look back at the Highlighted study. Its findings bring home the challenge to managers of setting
parameters and procedures for making what could be the life or death decision on when to terminate treatment, and of establishing the
kinds of programmes which patients want to stay in and which avoid terminating treatment unnecessarily, yet productively challenge
patients and enforce limits required for safety and therapeutic work. That challenge is at its height when treatment duration can be
lifelong, as in methadone maintenance and allied treatments which substitute a safer, legal and less disruptive opioid drug for the one
the patient has become dependent on. As normally implemented, these act like a light switch: rapid remission in illegal heroin use when
switched on, rapid and life-threatening relapse on departure. The evidence has been there for decades and is particularly strong from
Scandinavia. From Norway we learn that patients who continue to use illegal drugs during treatment are still protected by that treatment,
and suffer around five times more drug-related health problems when they leave or are forced to leave. In the seminal US study, similar
patients were also the ones who tended to die after being forced off the programme; in the following year, five of 43, all among the 20
who had not transferred to another programme. Terminating these patients’ treatment on the grounds that they are not benefiting
(enough) exposes them to even greater risks. This was one of the issues faced by a government-initiated expert review of methadone and
allied programmes in England, and faced again when seemingly not satisfied with the initial report, via the Chief Medical Officer the
government asked the experts to look again at how and when clinicians should review continuation of a patient’s treatment. Take a look
at the group’s response. Is it clear enough, should it have been more explicit about when to terminate, or is this best left as a judgement
call between the patient and their clinicians? Bear in mind that (as seems likely be increasingly the case) when treatment slots are too
few to meet demand, each patient kept in treatment on the grounds that they might partially be benefiting, blocks a slot for another
patient who might benefit more. Yet as a patient, you may feel you have the right to have your welfare centre stage rather than weighed
in the balance with that of potential patients.
 Are the days of needle ‘exchange’ behind us? ‘Exchange’ used to be a distinctive and essential element of needle exchange services –
that new sterile injecting equipment would be supplied (more or less strictly) in return for used equipment, taking these potential disease
carriers out of circulation and keeping the streets clear enough of needles and syringes to defuse opposition to ‘colluding’ with illegal
drug use and attracting ‘junkies’ to the neighbourhood. In the early days of needle exchange, the ‘return rate’ was a key statistic – a
badge of respectability. From the fieldwork conducted for NICE in preparation for their recommendations on needle exchange, it seems
these days this former priority lingers on only as a residual unenforced ambition honoured almost entirely in the breach. “Unrestricted
distribution” is now the norm, and insisting on return of used equipment before new equipment is supplied is seen as a barrier to
ensuring every injector has more than enough equipment to inject safely every time, the main hope for appreciably intercepting
transmission of the very transmissible hepatitis C virus. Instead of returns to the exchanges, ‘drop boxes’ or safe bins where injectors can
dispose of their equipment have gained greater prominence. In Britain, do any of the original reasons for the exchange policy still hold to
any degree? According to the research report on the original schemes, these were:
• To stop used and possibly infected needles being left in public and other places, or otherwise disposed of in a way that may be
hazardous to others.
• Exchanging syringes makes it less likely that syringes will be circulated and reused.
• Making the client return to the agency frequently increases the opportunity for advice and counselling.
• Needle exchange schemes would find it difficult to operate if there were substantial complaints from the public about discarded
syringes.
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